• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Masticatory Muscle Myositis in Dogs

January 15, 2019
Natalie Stilwell, DVM, MS, PhD

A recent study described the presenting signs, treatment, and outcome for 22 cases.

Masticatory muscle myositis (MMM) is an immune-mediated myopathy characterized by inflammation, necrosis, and atrophy of the masticatory muscles. In a recent study, researchers at the University of Pennsylvania School of Veterinary Medicine addressed a lack of existing literature on MMM by describing 22 cases of canine MMM treated at the school’s veterinary hospital over a 17-year period.

Patient Presentation

Patients included 13 male and 9 female dogs averaging 3.6 years and 27.7 kg in age and weight, respectively. The most commonly represented pure breeds were golden retriever and Rottweiler; 27% of dogs were classified as mixed breed.

Owners reported clinical signs lasting 4 days to 4.5 months before initial examination. Signs included lethargy, facial pain, drooling, vocal changes, gagging, exophthalmos, inappetance, and reduced play behavior. At presentation, all dogs were partially or completely unable to open the mouth, and many dogs exhibited facial pain, masticatory muscle swelling and/or atrophy, regional lymph node enlargement, and/or elevated body temperature. Blood chemistry abnormalities included hyperglobulinemia, hyperproteinemia, and increased liver enzymes.

Diagnosis and Treatment of Masticatory Muscle Myositis

Diagnosis was confirmed in all 22 dogs via immunohistochemistry and/or serum titer of 2M fiber antibodies. Diagnostic imaging performed for 12 dogs also indicated alterations in masticatory muscle size and appearance. Eleven of these dogs received a single dose of intravenous dexamethasone under general anesthesia because of a presumptive diagnosis of MMM.

Upon diagnosis of MMM, all dogs were prescribed immunosuppressive doses of oral prednisone (at least 1 mg/kg per 12 hours) for a mean of 3.5 weeks. Based on clinical signs, medication side effects, and repeat 2M fiber antibody titers, the initial prednisone dose was tapered by 25% to 50% every 2 to 8 weeks. Dose was tapered as low as possible to keep MMM in remission while minimizing side effects, such as polyuria, polydipsia, polyphagia, and diarrhea.

Advertisement

Patient Outcome

Masticatory muscle function and acceptable mandibular range of motion returned for 91% of the dogs for which follow-up information was available. In most cases, improvement was first observed within 1 to 3 days of treatment and plateaued after the first 4 weeks of prednisone therapy. All dogs exhibited some degree of masticatory muscle wasting at follow-up visits, and 5 dogs also developed general muscle wasting from prednisone therapy.

Prednisone was discontinued successfully in 10 dogs, whereas MMM relapse in 6 dogs required continued administration of low-dose prednisone. Relapse was not associated with initial dose or duration of immunosuppressive prednisone therapy, initial mandibular range of motion, initial 2M fiber antibody titer, or initial recovery time before relapse.

Before publication, 1 dog was euthanized due to adverse effects of prednisone administration, and 11 dogs died or were euthanized due to causes unrelated to MMM or its treatment.

Conclusions

In the study, MMM generally carried a favorable prognosis when treated promptly with immunosuppressive doses of prednisone. Dogs typically regained normal masticatory function within 4 weeks of treatment, although 27% of affected dogs experienced relapse that resolved with continued glucocorticoid therapy.

Dr. Stilwell provides freelance medical writing and aquatic veterinary consulting services through her business, Seastar Communications and Consulting. In addition to her DVM obtained from Auburn University, she holds a MS in fisheries and aquatic sciences and a PhD in veterinary medical sciences from the University of Florida.


Advertisement

Latest News

Viticus group seeks applications for veterinary boot camp scholarship

Unusual parasite strain kills 4 California sea otters

Q&A with a keynote: Jan Bellows, DVM, DAVDC, DABVP, FAVD

Evaluating liver enzyme elevation

View More Latest News
Advertisement